These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16258224)

  • 1. Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Ikeda S
    Intern Med; 2005 Sep; 44(9):1009-12. PubMed ID: 16258224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica].
    Yamane T; Yamauchi H; Abe N; Torio N; Shimada R; Senba T; Imaizumi Y; Nomura T
    Ryumachi; 2003 Jun; 43(3):544-8. PubMed ID: 12910963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
    Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
    Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
    Salvarani C; Cantini F; Niccoli L; Macchioni P; Consonni D; Bajocchi G; Vinceti M; Catanoso MG; Pulsatelli L; Meliconi R; Boiardi L
    Arthritis Rheum; 2005 Feb; 53(1):33-8. PubMed ID: 15696567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal.
    Corrigall VM; Dolan AL; Dasgupta B; Panayi GS
    Br J Rheumatol; 1997 Sep; 36(9):976-80. PubMed ID: 9376994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.
    Schreiber S; Buyse M
    Clin Rheumatol; 1995 May; 14(3):315-8. PubMed ID: 7641508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.
    McCarthy EM; MacMullan PA; Al-Mudhaffer S; Madigan A; Donnelly S; McCarthy CJ; Molloy ES; Kenny D; McCarthy GM
    J Rheumatol; 2014 May; 41(5):931-7. PubMed ID: 24692520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
    Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
    Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3 cases of polymyalgia rheumatica (PMR), in which serum amyloid A was a useful index of the disease activity].
    Yamane T; Yamauchi H; Imaizumi Y; Senba T
    Ryumachi; 2001 Aug; 41(4):756-62. PubMed ID: 11577405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
    Kyle V; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis.
    Pountain GD; Calvin J; Hazleman BL
    Br J Rheumatol; 1994 Jun; 33(6):550-4. PubMed ID: 8205403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
    Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
    Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).
    Leeb BF; Bird HA; Nesher G; Andel I; Hueber W; Logar D; Montecucco CM; Rovensky J; Sautner J; Sonnenblick M
    Ann Rheum Dis; 2003 Dec; 62(12):1189-94. PubMed ID: 14644857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease.
    Hachulla E; Saile R; Parra HJ; Hatron PY; Gosset D; Fruchart JC; Devulder B
    Clin Exp Rheumatol; 1991; 9(2):157-63. PubMed ID: 1711943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic difficulties in polymyalgia rheumatica cases with normal erythrocyte sedimentation rate and C-reactive protein values.
    Kara M; Alp G; Koç AM
    Medicine (Baltimore); 2023 Sep; 102(39):e35385. PubMed ID: 37773830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood lymphocyte subsets in polymyalgia rheumatica.
    Uddhammar A; Roos G; Näsman B; Dahlqvist SR
    Clin Rheumatol; 1995 Jan; 14(1):62-7. PubMed ID: 7743746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum soluble CD4 and CD8 levels in polymyalgia rheumatica.
    Salvarani C; Boiardi L; Macchioni P; Casadei Maldini M; Mancini R; Beltrandi E; Rossi F; Portioli I
    J Rheumatol; 1994 Oct; 21(10):1865-9. PubMed ID: 7837152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study.
    Mallya RK; Hind CR; Berry H; Pepys MB
    Arthritis Rheum; 1985 Apr; 28(4):383-7. PubMed ID: 2859021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.
    Kyle V; Cawston TE; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):667-71. PubMed ID: 2782977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrocyte sedimentation rate (ESR) at presentation is a prognostic indicator for duration of treatment in polymyalgia rheumatica (PMR).
    Pountain G; Hazleman B
    Br J Rheumatol; 1997 Apr; 36(4):508-9. PubMed ID: 9159557
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.